![Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency - Annals of Oncology Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/002260f5-01c2-4c61-9940-bd2f9ec5194e/gr1.jpg)
Acceptance of surrogate end points in clinical trials supporting approval of drugs for cancer treatment by the Japanese regulatory agency - Annals of Oncology
![Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action - Clinical Therapeutics Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/ef516152-b450-4bdd-9956-01a9a9b006be/gr1_lrg.jpg)
Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action - Clinical Therapeutics
![COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays - Wang - 2021 - Medicinal Research Reviews - Wiley Online Library COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays - Wang - 2021 - Medicinal Research Reviews - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0737968d-f250-4f87-a332-cb7af4c4af59/med21728-fig-0001-m.jpg)
COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays - Wang - 2021 - Medicinal Research Reviews - Wiley Online Library
![The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review - The Lancet Regional Health – Western Pacific The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review - The Lancet Regional Health – Western Pacific](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/24f9d65d-cf21-442e-8df1-6f76e4f419ac/gr1.jpg)
The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005–2020): A systematic review - The Lancet Regional Health – Western Pacific
![ATLAS Project – Paving the way towards developing drugs with Asian partners | National Cancer Center Japan ATLAS Project – Paving the way towards developing drugs with Asian partners | National Cancer Center Japan](https://www.ncc.go.jp/en/information/press_release/20200909/01.png)
ATLAS Project – Paving the way towards developing drugs with Asian partners | National Cancer Center Japan
![Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a16b0a8e-28c9-4625-8b08-478b4d483e52/gr1.gif)
Changes in clinical trials of cancer drugs in mainland China over the decade 2009–18: a systematic review - The Lancet Oncology
![Frontiers | The Current Status and Future Direction of Clinical Research in Japan From a Regulatory Perspective | Medicine Frontiers | The Current Status and Future Direction of Clinical Research in Japan From a Regulatory Perspective | Medicine](https://www.frontiersin.org/files/Articles/816921/fmed-08-816921-HTML/image_m/fmed-08-816921-g001.jpg)